Related Experiment Video
Updated: Dec 23, 2025

A Double Humanized BLT-mice Model Featuring a Stable Human-Like Gut Microbiome and Human Immune System
Published on: August 30, 2019
Gut Microbiome and the Response to Immunotherapy in Cancer
1Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Harvard Institute of Medicine, 4 Blackfan Circle, Boston, MA, 02215, USA.
Abstract:
Recent studies indicate that the composition of gut bacteria can influence the effectiveness of certain cancer immunotherapy drugs and that modulating the gut microbiome may expand the pool of patients benefiting from cancer immunotherapies. Checkpoint blockade therapy has been effective on several types of malignancies (e.g. melanoma, lung cancer, kidney cancer). However, the number of patients that do not respond, or only partially respond, to cancer immunotherapy is high. Recently, several human and mouse studies have shown that gut microbiome may be a significant determinant of the response to cancer immunotherapy. This review focuses on the recent advances in our understanding of the interaction between human gut microbiome and response to immunotherapy in cancer. The gut microbiome may serve as a theranostic biomarker, by acting both as a useful prognostic biomarker and a target in cancer therapy.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
The Tumor Microenvironment
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Psychoneuroimmunology: Diabetes and Cancer
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

